100 Evidence for decision making throughout the product life-span

Dr Jianjun Ren,Prof Wei Xu,Dr Jie Su,Dr Xue Ren,Dr Bayardo Perez-Ordonez,Mr Kevin Boyd,Dr Dangxiao Cheng,Dr Zhuo,Chen,Dr Noemi Bender,Tim Waterboer,Shao Hui Huang,Prof Yu Zhao,Geoffrey Liu,Zhen-Cheng Huang,Zai-Wei Song,Rong-Sheng Zhao
2018-01-01
Abstract:The costs of developing a medicine are increasing yet the potential target populations are decreasing. Innovative medicines are treating previously untreatable diseases but there is still huge unmet medical need. The costs to the health care systems of providing these innovative treatments are rapidly becoming unsustainable for even the richest countries. For a patient to get access to a medicine, several different decisions need to be made by different stakeholders including regulators, payers, physicians and the patient themselves. The evidence required for these decisions is different but is not always being provided so decision makers have to make important decisions based on incomplete information. This is not in anyone’s best interests. We need to change how we approach drug development and how we can deal with uncertainty.
What problem does this paper attempt to address?